Does tenofovir alafenamide fumarate tablets (Vemlidy) need to be taken for life and the risk of discontinuation?

Tenofovir alafenamide fumarate tablets (Vemlidy) is an oral nucleotide reverse transcriptase inhibitor mainly used to treat chronic hepatitis B (CHB). It inhibits the replication of hepatitis B virus (HBV), effectively reduces serum HBV DNA levels, improves liver function, and reduces the risk of liver fibrosis progression. Since the drug affects the viral replication process rather than curing the virus, most patients need to take the drug for a long time, or even for life, to maintain the viral suppression effect.

In clinical practice, Vemlidy is usually suitable for patients with high hepatitis B viral load or abnormal liver function. Stopping treatment may lead to viral rebound, rapid increase in serum HBV DNA, and some patients may even develop acute hepatitis or worsening of liver function. Especially in patients with cirrhosis or hepatic insufficiency, sudden discontinuation may cause severe liver injury or liver failure, so the risk of discontinuation must be carefully assessed.

In special circumstances, some patients may try to discontinue medication under strict medical supervision, such as patients with long-term HBV DNA persistent negative status, stable liver function, and no risk of cirrhosis. Close follow-up is required after stopping the drug, and changes in serum HBV DNA, liver function and liver imaging should be monitored every 1 to 3 months. Once viral rebound or abnormal liver function occurs, drug treatment should be resumed promptly to avoid serious complications.

Generally speaking, most patients need long-term use of tenofovir alafenamide fumarate tablets (Vemlidy) in the treatment of chronic hepatitis B, and there is a high risk of drug discontinuation. Patients should develop an individualized medication plan under the guidance of a professional doctor to avoid discontinuing medication on their own, and at the same time regularly review viral load and liver function indicators to ensure treatment safety and stable efficacy.

Reference link:https://www.drugs.com